Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:MIER1-LEPR

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: MIER1-LEPR
	FusionPDB ID: 53628
	FusionGDB2.0 ID: 53628
		Hgene	Tgene
	Gene symbol	MIER1	LEPR
	Gene ID	57708	54741
	Gene name	MIER1 transcriptional regulator	leptin receptor overlapping transcript
	Synonyms	ER1\|MI-ER1	LEPR\|OB-RGRP\|OBRGRP\|VPS55
	Cytomap	1p31.3	1p31.3
	Type of gene	protein-coding	protein-coding
	Description	mesoderm induction early response protein 1mesoderm induction early response 1 homologmesoderm induction early response 1, transcriptional regulator	leptin receptor gene-related proteinDnaJ (Hsp40) homolog, subfamily C, member 6OB-R gene-related proteinendospaninendospanin-1leptin receptor overlapping transcript protein
	Modification date	20200313	20200320
	UniProtAcc	Q8N108 Main function of 5'-partner protein: FUNCTION: Transcriptional repressor regulating the expression of a number of genes including SP1 target genes. Probably functions through recruitment of HDAC1 a histone deacetylase involved in chromatin silencing. {ECO:0000269\|PubMed:12482978}.	O95214 Main function of 5'-partner protein: FUNCTION: Negatively regulates growth hormone (GH) receptor cell surface expression in liver. May play a role in liver resistance to GH during periods of reduced nutrient availability. {ECO:0000269\|PubMed:19907080}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000479067, ENST00000355356, ENST00000357692, ENST00000371012, ENST00000371014, ENST00000371016, ENST00000371018, ENST00000401041, ENST00000401042, ENST00000355977,	ENST00000344610, ENST00000349533, ENST00000371059, ENST00000371060, ENST00000371058, ENST00000462765, ENST00000406510,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	6 X 5 X 3=90	8 X 9 X 4=288
	# samples	6	9
	** MAII score	log2(6/90*10)=-0.584962500721156 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(9/288*10)=-1.67807190511264 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: MIER1 [Title/Abstract] AND LEPR [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: MIER1 [Title/Abstract] AND LEPR [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	MIER1(67405735)-LEPR(66036156), # samples:2
Anticipated loss of major functional domain due to fusion event.	MIER1-LEPR seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MIER1-LEPR seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. MIER1-LEPR seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. MIER1-LEPR seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	MIER1	GO:0016575	histone deacetylation	28046085
Hgene	MIER1	GO:0031937	positive regulation of chromatin silencing	12482978
Tgene	LEPR	GO:0046426	negative regulation of JAK-STAT cascade	18042720
Tgene	LEPR	GO:0060400	negative regulation of growth hormone receptor signaling pathway	19907080
Tgene	LEPR	GO:2000009	negative regulation of protein localization to cell surface	18042720

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:67405735/chr1:66036156)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across MIER1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across LEPR (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000371018	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	3082	401	262	3081	940
ENST00000371018	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3255	401	262	3237	991
ENST00000371018	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5311	401	262	3051	929
ENST00000371018	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8403	401	262	3858	1198
ENST00000357692	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	3023	342	200	3022	941
ENST00000357692	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3196	342	200	3178	992
ENST00000357692	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5252	342	200	2992	930
ENST00000357692	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8344	342	200	3799	1199
ENST00000401041	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	2944	263	70	2943	958
ENST00000401041	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3117	263	70	3099	1009
ENST00000401041	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5173	263	70	2913	947
ENST00000401041	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8265	263	70	3720	1216
ENST00000371016	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	3018	337	198	3017	939
ENST00000371016	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3191	337	198	3173	991
ENST00000371016	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5247	337	198	2987	929
ENST00000371016	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8339	337	198	3794	1198
ENST00000371014	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	2944	263	70	2943	958
ENST00000371014	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3117	263	70	3099	1009
ENST00000371014	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5173	263	70	2913	947
ENST00000371014	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8265	263	70	3720	1216
ENST00000371012	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	3010	329	190	3009	940
ENST00000371012	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3183	329	190	3165	991
ENST00000371012	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5239	329	190	2979	929
ENST00000371012	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8331	329	190	3786	1198
ENST00000401042	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	2864	183	149	2863	905
ENST00000401042	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3037	183	149	3019	956
ENST00000401042	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5093	183	149	2833	894
ENST00000401042	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8185	183	149	3640	1163
ENST00000355356	MIER1	chr1	67405735	+	ENST00000344610	LEPR	chr1	66036156	+	2864	183	149	2863	905
ENST00000355356	MIER1	chr1	67405735	+	ENST00000371059	LEPR	chr1	66036156	+	3037	183	149	3019	956
ENST00000355356	MIER1	chr1	67405735	+	ENST00000371060	LEPR	chr1	66036156	+	5093	183	149	2833	894
ENST00000355356	MIER1	chr1	67405735	+	ENST00000349533	LEPR	chr1	66036156	+	8185	183	149	3640	1163

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000371018	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000184693	0.9998153
ENST00000371018	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000141804	0.99985814
ENST00000371018	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000125304	0.9998747
ENST00000371018	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000235184	0.99976486
ENST00000357692	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000176771	0.9998233
ENST00000357692	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.00012726	0.9998727
ENST00000357692	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000123647	0.9998764
ENST00000357692	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000215878	0.9997842
ENST00000401041	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000153389	0.9998466
ENST00000401041	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000301175	0.9996989
ENST00000401041	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000102791	0.99989724
ENST00000401041	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000149819	0.99985015
ENST00000371016	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000176244	0.99982375
ENST00000371016	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.00012649	0.9998735
ENST00000371016	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000122748	0.9998772
ENST00000371016	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000215068	0.9997849
ENST00000371014	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000153389	0.9998466
ENST00000371014	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000301175	0.9996989
ENST00000371014	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000102791	0.99989724
ENST00000371014	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000149819	0.99985015
ENST00000371012	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000176956	0.99982303
ENST00000371012	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000125331	0.9998747
ENST00000371012	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000123558	0.9998764
ENST00000371012	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.00021255	0.9997875
ENST00000401042	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000208077	0.9997919
ENST00000401042	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000150049	0.9998499
ENST00000401042	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000157134	0.9998429
ENST00000401042	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000179349	0.99982065
ENST00000355356	ENST00000344610	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000208077	0.9997919
ENST00000355356	ENST00000371059	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000150049	0.9998499
ENST00000355356	ENST00000371060	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000157134	0.9998429
ENST00000355356	ENST00000349533	MIER1	chr1	67405735	+	LEPR	chr1	66036156	+	0.000179349	0.99982065

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for MIER1-LEPR

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
MIER1	chr1	67405735	LEPR	chr1	66036156	263	64	TDVMLPSVESSSPEFIYVITAFNLSY
MIER1	chr1	67405735	LEPR	chr1	66036156	329	46	LSNYQPSVESSSPEFIYVITAFNLSY
MIER1	chr1	67405735	LEPR	chr1	66036156	337	46	LSNYQPSVESSSPEFIYVITAFNLSY
MIER1	chr1	67405735	LEPR	chr1	66036156	342	47	LSNYQPSVESSSPEFIYVITAFNLSY
MIER1	chr1	67405735	LEPR	chr1	66036156	401	46	LSNYQPSVESSSPEFIYVITAFNLSY

Top

Potential FusionNeoAntigen Information of MIER1-LEPR in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

MIER1-LEPR_67405735_66036156.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:01	VESSSPEF	0.99	0.9227	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A02:35	SSSPEFIYV	0.9806	0.6839	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A02:21	SSSPEFIYV	0.9731	0.7941	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A02:20	SSSPEFIYV	0.9615	0.6717	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B13:01	VESSSPEFI	0.9523	0.7373	7	16
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:08	SVESSSPEF	0.9111	0.9162	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:02	SVESSSPEF	0.8877	0.938	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:25	SVESSSPEF	0.8768	0.9267	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:08	ESSSPEFIY	0.8524	0.7705	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:01	SVESSSPEF	0.8439	0.9086	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A30:08	SSSPEFIYV	0.7984	0.6857	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B52:01	SSSPEFIYV	0.6804	0.6697	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:01	ESSSPEFIY	0.6778	0.8083	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B41:01	VESSSPEFI	0.2116	0.7939	7	16
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B39:13	VESSSPEFI	0.0061	0.7504	7	16
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B44:03	VESSSPEFIY	0.9458	0.8901	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B45:01	SPEFIYVITA	0.8528	0.6877	11	21
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:01	LPSVESSSPEF	0.9991	0.8836	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:08	LPSVESSSPEF	0.999	0.9186	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:05	LPSVESSSPEF	0.9973	0.6666	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:03	LPSVESSSPEF	0.994	0.9024	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	342	HLA-B35:01	QPSVESSSPEF	0.9805	0.909	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	342	HLA-B35:08	QPSVESSSPEF	0.9795	0.8033	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:04	LPSVESSSPEF	0.9757	0.9045	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:02	LPSVESSSPEF	0.9757	0.9045	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:17	SSPEFIYV	0.9839	0.9592	10	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:30	SSPEFIYV	0.9472	0.9754	10	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C05:09	SSSPEFIYV	0.9995	0.9655	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:06	SSSPEFIYV	0.9995	0.9306	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:06	SSSPEFIYV	0.9995	0.854	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:07	SSSPEFIYV	0.9994	0.9865	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:04	SSSPEFIYV	0.9991	0.9111	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C05:09	SVESSSPEF	0.999	0.9204	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:07	SVESSSPEF	0.9988	0.7711	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:10	SVESSSPEF	0.9988	0.7578	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:06	SSPEFIYVI	0.9968	0.8866	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:15	SVESSSPEF	0.9966	0.9448	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:06	SSPEFIYVI	0.9927	0.7622	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:19	SSSPEFIYV	0.9897	0.9908	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:08	SSSPEFIYV	0.9896	0.8977	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C12:04	SSSPEFIYV	0.9794	0.9951	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:03	SSSPEFIYV	0.9739	0.995	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:13	SSSPEFIYV	0.9627	0.9622	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:04	SSSPEFIYV	0.9627	0.9622	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B40:06	PEFIYVITA	0.9572	0.5149	12	21
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A02:07	SSSPEFIYV	0.9552	0.6637	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C12:04	SSPEFIYVI	0.9089	0.9905	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:03	SSPEFIYVI	0.9086	0.9902	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C12:12	SSSPEFIYV	0.9013	0.9304	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:21	SVESSSPEF	0.8928	0.9318	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C12:12	SSPEFIYVI	0.8716	0.892	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:05	SVESSSPEF	0.8425	0.882	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:31	SVESSSPEF	0.8411	0.8896	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:03	SSSPEFIYV	0.7675	0.9854	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C07:13	SSPEFIYVI	0.7658	0.8362	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C02:06	SSSPEFIYV	0.7609	0.9851	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:17	SSPEFIYVI	0.7154	0.9138	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:31	ESSSPEFIY	0.674	0.7598	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:30	SSPEFIYVI	0.6345	0.9432	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:07	SVESSSPEF	0.5895	0.9917	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C02:06	SSPEFIYVI	0.5401	0.9732	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:14	SSSPEFIYV	0.5217	0.984	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:06	SVESSSPEF	0.342	0.8146	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:14	SVESSSPEF	0.2693	0.9866	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:04	SVESSSPEF	0.1678	0.9397	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:13	SVESSSPEF	0.1678	0.9397	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B39:08	VESSSPEFI	0.064	0.6333	7	16
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:03	SVESSSPEF	0.0621	0.9585	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B40:06	SPEFIYVITA	0.7956	0.5541	11	21
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B07:12	LPSVESSSPEF	0.9963	0.6371	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:12	LPSVESSSPEF	0.9757	0.9045	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:03	SSPEFIYV	0.9975	0.9369	10	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:02	SSPEFIYV	0.9951	0.957	10	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:08	VESSSPEF	0.9925	0.8209	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:06	VESSSPEF	0.9912	0.9339	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:05	VESSSPEF	0.99	0.9227	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:04	VESSSPEF	0.9895	0.9277	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:03	VESSSPEF	0.985	0.9158	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:11	VESSSPEF	0.9719	0.8899	7	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:02	SSSPEFIYV	0.9997	0.8948	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:05	SSSPEFIYV	0.9996	0.8993	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:03	SSSPEFIYV	0.9995	0.9061	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C05:01	SSSPEFIYV	0.9995	0.9655	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:04	SSSPEFIYV	0.9991	0.8331	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:09	SSSPEFIYV	0.9991	0.9111	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:03	SVESSSPEF	0.9991	0.8242	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C05:01	SVESSSPEF	0.999	0.9204	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C04:01	SVESSSPEF	0.9988	0.7711	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C18:01	SVESSSPEF	0.9984	0.7833	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:02	SSPEFIYVI	0.9979	0.8455	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:06	SSSPEFIYV	0.9977	0.9934	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C15:05	SSPEFIYVI	0.9966	0.8648	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:02	SVESSSPEF	0.9966	0.9448	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A69:01	SSSPEFIYV	0.9962	0.8233	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:17	SSSPEFIYV	0.9944	0.9739	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C16:02	SSSPEFIYV	0.9915	0.9928	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:06	SSSPEFIYV	0.9849	0.9906	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:17	SSPEFIYVI	0.9813	0.9221	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B40:04	VESSSPEFI	0.9753	0.5483	7	16
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A02:06	SSSPEFIYV	0.9731	0.7941	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A02:14	SSSPEFIYV	0.973	0.7022	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C16:04	SSSPEFIYV	0.9725	0.9865	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C16:02	SSPEFIYVI	0.9601	0.9883	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C16:04	SSPEFIYVI	0.9268	0.974	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:02	SSSPEFIYV	0.9231	0.9946	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:17	SSSPEFIYV	0.9231	0.9946	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C16:01	SSSPEFIYV	0.9118	0.9843	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C12:03	SSSPEFIYV	0.9083	0.9845	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:17	SSPEFIYVI	0.8875	0.9895	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:02	SSPEFIYVI	0.8875	0.9895	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C12:03	SSPEFIYVI	0.8798	0.9715	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A25:01	ESSSPEFIY	0.8754	0.6311	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:20	SVESSSPEF	0.8584	0.9147	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:39	SVESSSPEF	0.8583	0.8572	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:02	SVESSSPEF	0.8575	0.9734	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:11	SVESSSPEF	0.852	0.9207	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:04	SVESSSPEF	0.8467	0.9925	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:03	SVESSSPEF	0.8467	0.9925	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:77	SVESSSPEF	0.8439	0.9086	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C17:01	SSSPEFIYV	0.8391	0.8516	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:23	SVESSSPEF	0.8369	0.8094	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:20	SVESSSPEF	0.8194	0.9289	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:03	SSPEFIYVI	0.8185	0.8607	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:28	SVESSSPEF	0.8159	0.9126	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C01:02	SSPEFIYVI	0.8023	0.9095	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:01	SSSPEFIYV	0.7675	0.9854	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:13	SVESSSPEF	0.736	0.5629	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:77	ESSSPEFIY	0.6778	0.8083	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:23	ESSSPEFIY	0.6775	0.7144	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C17:01	SSPEFIYVI	0.6736	0.5938	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:20	ESSSPEFIY	0.6421	0.8374	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C07:04	SSSPEFIYV	0.6199	0.9536	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:08	SSSPEFIYV	0.6061	0.9934	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:08	SVESSSPEF	0.5718	0.8967	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:24	ESSSPEFIY	0.5088	0.7745	8	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C06:08	SSPEFIYVI	0.5018	0.9821	10	19
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C02:02	SSSPEFIYV	0.5003	0.9877	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C02:10	SSSPEFIYV	0.5003	0.9877	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C03:06	SVESSSPEF	0.3391	0.9931	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B07:13	SVESSSPEF	0.2319	0.8833	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-C08:01	SVESSSPEF	0.0621	0.9585	6	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B07:13	SSSPEFIYV	0.0181	0.873	9	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A68:02	ESSSPEFIYV	0.999	0.517	8	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-A69:01	ESSSPEFIYV	0.9979	0.8133	8	18
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B44:13	VESSSPEFIY	0.9458	0.8901	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B44:26	VESSSPEFIY	0.9458	0.8901	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B44:07	VESSSPEFIY	0.9458	0.8901	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B15:53	VESSSPEFIY	0.8687	0.7972	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B18:11	VESSSPEFIY	0.6489	0.8304	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B48:02	VESSSPEFIY	0.5485	0.744	7	17
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:77	LPSVESSSPEF	0.9991	0.8836	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:23	LPSVESSSPEF	0.999	0.8383	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:17	LPSVESSSPEF	0.9979	0.7863	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:30	LPSVESSSPEF	0.9979	0.7863	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:43	LPSVESSSPEF	0.9971	0.8326	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:24	LPSVESSSPEF	0.9942	0.8439	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:11	LPSVESSSPEF	0.9935	0.8995	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:30	SPEFIYVITAF	0.992	0.5507	11	22
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:17	SPEFIYVITAF	0.992	0.5507	11	22
MIER1-LEPR	chr1	67405735	chr1	66036156	342	HLA-B35:77	QPSVESSSPEF	0.9805	0.909	4	15
MIER1-LEPR	chr1	67405735	chr1	66036156	263	HLA-B35:09	LPSVESSSPEF	0.9757	0.9045	4	15

Top

Potential FusionNeoAntigen Information of MIER1-LEPR in HLA II

MIER1-LEPR_67405735_66036156.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
MIER1-LEPR	chr1	67405735	chr1	66036156	342	DRB1-0901	LSNYQPSVESSSPEF	0	15
MIER1-LEPR	chr1	67405735	chr1	66036156	342	DRB1-0902	LSNYQPSVESSSPEF	0	15
MIER1-LEPR	chr1	67405735	chr1	66036156	342	DRB1-0908	LSNYQPSVESSSPEF	0	15
MIER1-LEPR	chr1	67405735	chr1	66036156	342	DRB1-0909	LSNYQPSVESSSPEF	0	15

Top

Fusion breakpoint peptide structures of MIER1-LEPR

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
9143	SVESSSPEFIYVIT	MIER1	LEPR	chr1	67405735	chr1	66036156	263

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
9143	SVESSSPEFIYVIT	MIER1	LEPR	chr1	67405735	chr1	66036156	342

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of MIER1-LEPR

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	9143	SVESSSPEFIYVIT	-7.15543	-7.26883
HLA-B14:02	3BVN	9143	SVESSSPEFIYVIT	-4.77435	-5.80965
HLA-B52:01	3W39	9143	SVESSSPEFIYVIT	-6.80875	-6.92215
HLA-B52:01	3W39	9143	SVESSSPEFIYVIT	-4.20386	-5.23916
HLA-A11:01	4UQ2	9143	SVESSSPEFIYVIT	-7.5194	-8.5547
HLA-A11:01	4UQ2	9143	SVESSSPEFIYVIT	-6.9601	-7.0735
HLA-A24:02	5HGA	9143	SVESSSPEFIYVIT	-7.52403	-7.63743
HLA-A24:02	5HGA	9143	SVESSSPEFIYVIT	-5.82433	-6.85963
HLA-B27:05	6PYJ	9143	SVESSSPEFIYVIT	-3.28285	-4.31815
HLA-B44:05	3DX8	9143	SVESSSPEFIYVIT	-5.91172	-6.94702
HLA-B44:05	3DX8	9143	SVESSSPEFIYVIT	-4.24346	-4.35686
HLA-B14:02	3BVN	9143	SVESSSPEFIYVIT	-7.15543	-7.26883
HLA-B14:02	3BVN	9143	SVESSSPEFIYVIT	-4.77435	-5.80965
HLA-B52:01	3W39	9143	SVESSSPEFIYVIT	-6.80875	-6.92215
HLA-B52:01	3W39	9143	SVESSSPEFIYVIT	-4.20386	-5.23916
HLA-A11:01	4UQ2	9143	SVESSSPEFIYVIT	-7.5194	-8.5547
HLA-A11:01	4UQ2	9143	SVESSSPEFIYVIT	-6.9601	-7.0735
HLA-A24:02	5HGA	9143	SVESSSPEFIYVIT	-7.52403	-7.63743
HLA-A24:02	5HGA	9143	SVESSSPEFIYVIT	-5.82433	-6.85963
HLA-B27:05	6PYJ	9143	SVESSSPEFIYVIT	-3.28285	-4.31815
HLA-B44:05	3DX8	9143	SVESSSPEFIYVIT	-5.91172	-6.94702
HLA-B44:05	3DX8	9143	SVESSSPEFIYVIT	-4.24346	-4.35686

Top

Vaccine Design for the FusionNeoAntigens of MIER1-LEPR

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
MIER1-LEPR	chr1	67405735	chr1	66036156	10	18	SSPEFIYV	CAAGTCCAGAATTTATTTATGTGA
MIER1-LEPR	chr1	67405735	chr1	66036156	10	19	SSPEFIYVI	CAAGTCCAGAATTTATTTATGTGATAA
MIER1-LEPR	chr1	67405735	chr1	66036156	11	21	SPEFIYVITA	GTCCAGAATTTATTTATGTGATAACTGCGT
MIER1-LEPR	chr1	67405735	chr1	66036156	11	22	SPEFIYVITAF	GTCCAGAATTTATTTATGTGATAACTGCGTTTA
MIER1-LEPR	chr1	67405735	chr1	66036156	12	21	PEFIYVITA	CAGAATTTATTTATGTGATAACTGCGT
MIER1-LEPR	chr1	67405735	chr1	66036156	4	15	LPSVESSSPEF	TGCCATCTGTTGAATCTTCAAGTCCAGAATTTA
MIER1-LEPR	chr1	67405735	chr1	66036156	4	15	QPSVESSSPEF	AGCCATCTGTTGAATCTTCAAGTCCAGAATTTA
MIER1-LEPR	chr1	67405735	chr1	66036156	6	15	SVESSSPEF	CTGTTGAATCTTCAAGTCCAGAATTTA
MIER1-LEPR	chr1	67405735	chr1	66036156	7	15	VESSSPEF	TTGAATCTTCAAGTCCAGAATTTA
MIER1-LEPR	chr1	67405735	chr1	66036156	7	16	VESSSPEFI	TTGAATCTTCAAGTCCAGAATTTATTT
MIER1-LEPR	chr1	67405735	chr1	66036156	7	17	VESSSPEFIY	TTGAATCTTCAAGTCCAGAATTTATTTATG
MIER1-LEPR	chr1	67405735	chr1	66036156	8	17	ESSSPEFIY	AATCTTCAAGTCCAGAATTTATTTATG
MIER1-LEPR	chr1	67405735	chr1	66036156	8	18	ESSSPEFIYV	AATCTTCAAGTCCAGAATTTATTTATGTGA
MIER1-LEPR	chr1	67405735	chr1	66036156	9	18	SSSPEFIYV	CTTCAAGTCCAGAATTTATTTATGTGA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
MIER1-LEPR	chr1	67405735	chr1	66036156	0	15	LSNYQPSVESSSPEF	TGTCAAATTACCAGCCATCTGTTGAATCTTCAAGTCCAGAATTTA

Top

Information of the samples that have these potential fusion neoantigens of MIER1-LEPR

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
SKCM	MIER1-LEPR	chr1	67405735	ENST00000357692	chr1	66036156	ENST00000344610	TCGA-GF-A2C7-01A
SKCM	MIER1-LEPR	chr1	67405735	ENST00000371014	chr1	66036156	ENST00000344610	TCGA-GF-A2C7-01A

Top

Potential target of CAR-T therapy development for MIER1-LEPR

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

LEPR

chr1:67405735

chr1:66036156

ENST00000344610

840_862

907.0

Transmembrane

Helical

Tgene

LEPR

chr1:67405735

chr1:66036156

ENST00000349533

840_862

1166.0

Transmembrane

Helical

Tgene

LEPR

chr1:67405735

chr1:66036156

ENST00000371058

840_862

907.0

Transmembrane

Helical

Tgene

LEPR

chr1:67405735

chr1:66036156

ENST00000371059

840_862

959.0

Transmembrane

Helical

Tgene

LEPR

chr1:67405735

chr1:66036156

ENST00000371060

840_862

897.0

Transmembrane

Helical

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to MIER1-LEPR

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to MIER1-LEPR

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)